More On The ASCO 2015 Abstracts — Some Other Day. . .

I’m just a little crispy tonight, so I’ll just use a picture — here is what at least one analyst ($ subs. req’d.) sees as the market, now to 2020.

Note that this crosses all cancers, and still has BMS’s nivolumab (in yellow below, branded as Opdivo®) as the clear leader. Here it is:

Sleep well, one and all. More some other day. I’m out.

Advertisements

There are no comments on this post.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: